Emricasan (IDN‐6556) Lowers Portal Pressure in Patients With Compensated Cirrhosis and Severe Portal Hypertension-Reference-Cited by-同舟云学术

Emricasan (IDN‐6556) Lowers Portal Pressure in Patients With Compensated Cirrhosis and Severe Portal Hypertension

Published:2018-11-26 Issue:2 Volume:69 Page:717-728
ISSN:0270-9139
Container-title:Hepatology
language:en
Short-container-title:Hepatology

Author:

Garcia‐Tsao Guadalupe¹,Fuchs Michael²,Shiffman Mitchell³,Borg Brian B.⁴,Pyrsopoulos Nikolaos⁵,Shetty Kirti⁶,Gallegos‐Orozco Juan F.⁷,Reddy K. Rajender⁸,Feyssa Eyob⁹,Chan Jean L.¹⁰,Yamashita Mason¹⁰,Robinson James M.¹⁰,Spada Alfred P.¹⁰,Hagerty David T.¹⁰,Bosch Jaime¹¹¹²

Affiliation:

1. Yale University and VA Connecticut Healthcare System New Haven CT

2. McGuire DVAMC Richmond VA

3. Liver Institute of Virginia Richmond VA

4. University of Mississippi Jackson MS

5. Rutgers New Jersey Medical School Newark NJ

6. Johns Hopkins Sibley Memorial Hospital Washington DC

7. University of Utah Salt Lake City UT

8. University of Pennsylvania Philadelphia PA

9. Division of Hepatology Albert Einstein Medical Center Philadelphia PA

10. Conatus Pharmaceuticals San Diego CA

11. Liver Unit, Hospital Clinic‐IDIBAPS University of Barcelona Barcelona Spain

12. Swiss Liver, Inselspital Bern University Bern Switzerland

Funder

Conatus Pharmaceuticals Inc.

Publisher

Wiley

Subject

Hepatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/hep.30199

Reference37 articles.

1. Hepatic Venous Pressure Gradient Predicts Clinical Decompensation in Patients With Compensated Cirrhosis

2. Evolution in the understanding of the pathophysiological basis of portal hypertension: How changes in paradigm are leading to successful new treatments

3. The Caspase Inhibitor IDN-6556 Attenuates Hepatic Injury and Fibrosis in the Bile Duct Ligated Mouse

4. The pan-caspase inhibitor Emricasan (IDN-6556) decreases liver injury and fibrosis in a murine model of non-alcoholic steatohepatitis

5. The pan‐caspase inhibitor emricasan improves the hepatic microcirculatory dysfunction of CCL4‐cirrhotic rats leading to portal hypertension amelioration and cirrhosis regression;Gracia‐Sancho J;Hepatology,2016

Cited by 69 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Recent advances in promising drugs for primary prevention of gastroesophageal variceal bleeding with cirrhotic portal hypertension;Hepatobiliary & Pancreatic Diseases International;2024-02

2. Current investigations for liver fibrosis treatment: between repurposing the FDA-approved drugs and the other emerging approaches;Journal of Pharmacy & Pharmaceutical Sciences;2023-11-07

3. ROS/RNS as molecular signatures of chronic liver diseases;Trends in Molecular Medicine;2023-11

4. Editorial: Mapping enzyme activity: from novel diagnostics to target-based therapeutics, how activity-based probes are improving our understanding of biological catalysts;Frontiers in Pharmacology;2023-08-22

5. The Protective Effect of Nutraceuticals on Hepatic Ischemia-Reperfusion Injury in Wistar Rats;International Journal of Molecular Sciences;2023-06-17